Back to Top

PAN Foundation Establishes Financial Assistance Program for Chronic Myeloid Leukemia Patients


Washington, D.C., June 7, 2014 – The Patient Access Network (PAN) Foundation is pleased to announce the launch of their newest financial assistance program, aimed at providing help and hope to patients being treated for Chronic Myeloid Leukemia (CML).

“The PAN Foundation is dedicated to providing assistance to patients who need it the most,” explained Patrick McKercher, PAN President. “By removing the financial burden of their medications, PAN is enabling patients with Chronic Myeloid Leukemia to focus on their wellness and quality of life, rather than how to afford their treatment costs.”

Qualifying patients are eligible to receive up to $7,500 per year to cover costs associated with their medications. Patients must have insurance that covers the medication for which they seek assistance, must have a household income must fall below 500 percent of the Federal Poverty Level and must reside and receive treatment in the United States.

About Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia (CML) is a type of cancer of the blood cells (also known as chronic granulocytic leukemia). This cancer tends to progress more slowly than acute forms of leukemia. About 10% of the different types of leukemias are CML. In CML, too many blood stem cells become a type of white blood cell called granulocytes. These granulocytes are abnormal and do not become healthy white blood cells. CML typically affects older adults and rarely occurs in children, though it can occur at any age.

About the PAN Foundation

Patient Access Network Foundation is dedicated to nationally providing help and hope to patients who would otherwise be unable to afford medications due to out-of-pocket costs. PAN provides assistance through nearly 60 disease-specific programs designed to help patients being treated for certain cancers, chronic illnesses, and rare diseases. Through our streamlined application process and state of the art online tools, we are able to ensure that eligible patients are put on the fast track to therapy.